| The following article features coverage from the American Society of Hematology 2020 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
Hospitalization burden has increased over the last decade, though in-hospital mortality has declined, among patients with multiple myeloma (MM), according to the results of a retrospective administrative database study presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
“This is the largest administrative database in the country,” which gave the researchers a look at the real-world picture that was applicable to a heterogenous population, Siddharth Bhesania, MBBS, of New York-Presbyterian Brooklyn Methodist Hospital in NYC, and presenter of the study, said.
The retrospective study analyzed data from 196,433 hospitalizations due to MM from the National Inpatient Sample database between 2007 and 2017. The primary endpoint was the estimation of hospitalizations and outcomes trends. The secondary aim was to identify factors predictive of poor outcomes.
Continue Reading
The median age of the cohort was 64 years, 55.5% were male, and 62.8% were Caucasian.
During the 10-year time frame of the study, hospitalization due to MM have increased from 17,100 in 2007 to 19,490 in 2017. However, in-hospital mortality decreased from 8.4% in 2007 to 4.9% in 2017 (P <.001). The overall in-hospital mortality rate was 6.5%. The rate of adverse hospital discharge remained similar, at 20% in 2007 compared with 18% in 2017 (P =.08).
The type of hospital where patients were admitted was associated with outcomes. In-hospital mortality was associated with care at a rural hospital (odds ratio [OR], 2.6; 95% CI, 1.9-2.7; P <.0001), a non-teaching hospital (OR, 1.4; 95% CI, 1.2-1.5; P <.0001), and a hospital with a small number of beds (OR, 1.3; 95% CI, 1.2-1.5; P <.0001).
Patients of increasing age (OR, 1.5; 95% CI, 1.3-1.5; P <.0001) or without insurance or who were self-pay were also more likely to die in hospital (OR, 2.6; 95% CI, 2.1-3.3; P <.0001).
Several in-hospital complications and comorbidities were associated with mortality as well, including septicemia, pneumonia, congestive heart failure, renal failure, and weight loss.
Dr Bhesania concluded that the team “observed that there is increased MM hospitalization over the years with a decline in in-hospital mortality — the reasons, we assume, were newer medications and updated guidelines for MM treatment.”
Disclosures: Some of the presenters disclosed financial relationships with the pharmaceutical industry and/or the medical device industry. For a full list of disclosures, please refer to the presentation abstract.
Read more of Cancer Therapy Advisor‘s coverage of the ASH 2020 meeting by visiting the conference page.
Reference
Bhesania S, Anand S, Dabria T, et al. Disparities in outcomes of hospitalizations due to multiple myeloma: a nationwide comparison. Presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; December 5-9, 2020. Abstract 211.
